<p>Prime Medicine, Inc. (NYSE:PRME - 獲取免費報告) 的股價在週一交易中下跌了 7.2%。該股最低交易價為$3.52，最後交易價為$3.5450。在交易中，共成交了 1,344,568 股，較平均交易量 2,896,184 股下降了 54%。該股此前收盤價為$3.82。</p>
<p>獲取 <strong>Prime Medicine</strong> 相關提醒：</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>2 只基因編輯股票值得在 2024 年關注</li>
</ul>
<p>多家券商對 PRME 進行了評估。Chardan Capital 將 Prime Medicine 的目標價從$10.00 下調至$9.00，並在 11 月 10 日的研究報告中給予該股 “買入” 評級。花旗集團將 Prime Medicine 的目標價從$5.00 下調至$4.25，並在 11 月 11 日的報告中給予該股 “中性” 評級。最後，Wedbush 在 11 月 10 日的研究報告中重申了 “跑贏大盤” 評級，並將 Prime Medicine 的目標價設定為$8.00。一位研究分析師給予該股 “強烈買入” 評級，四位分析師給予 “買入” 評級，三位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為$9.21。</p>
<p><strong>閲讀我們關於 PRME 的最新研究報告</strong></p>
<h2>Prime Medicine 價格表現</h2>
<p>該股的 50 日移動平均價格為$4.86，200 日移動平均價格為$3.70。該公司的市值為 6.4352 億美元，市盈率為-1.74，貝塔值為 2.64。</p>
<h2>對 Prime Medicine 的對沖基金看法</h2>
<p>多家大型投資者最近調整了對 PRME 的持股。Creative Planning 在第二季度新購入了 Prime Medicine 的股份，價值$25,000。Freedom Investment Management Inc.在第二季度購買了 Prime Medicine 的新股份，價值$26,000。R Squared Ltd 在第二季度新購入了 Prime Medicine 的股份，價值$31,000。JTC Employer Solutions Trustee Ltd 在第二季度新購入了 Prime Medicine 的股份，價值$33,000。最後，Savant Capital LLC 在第二季度新購入了 Prime Medicine 的股份，價值約$37,000。目前，70.37% 的股票由機構投資者和對沖基金持有。</p>
<h2>Prime Medicine 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Prime Medicine, Inc.是一家生物技術公司，通過部署基因編輯技術提供遺傳療法，以應對各種疾病。該公司提供 Prime Editors，包含一個 Prime Editor 蛋白質，由 Cas 蛋白和逆轉錄酶融合而成；以及一個 pegRNA，旨在將 Prime Editor 定位到特定基因組位置，並提供製作目標 DNA 序列所需編輯的模板。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Prime Medicine</li>
<li>投資者需要了解的擊敗市場的信息</li>
<li>如果 D-Wave 風險太大，請考慮這 3 只量子 ETF 進行多元化</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>NVIDIA 的 13F 揭示了 2 個第三季度贏家——以及 1 個痛苦的失誤</li>
<li>3 只最佳金融科技股票，助力投資組合提升</li>
<li>為什麼銀在 2025 年勝過黃金和標準普爾——接下來會發生什麼</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Prime Medicine 嗎？</h2>
<p>在考慮 Prime Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Prime Medicine 並不在名單上。</p>
<p>雖然 Prime Medicine 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PRME

<p>Prime Medicine 的股票（紐約證券交易所代碼：PRME）下跌了 7.2%，至 3.5450 美元，交易量較平均水平下降了 54%。分析師調整了目標價格：Chardan Capital 為 9.00 美元，花旗集團為 4.25 美元，Wedbush 為 8.00 美元。該股票的共識評級為 “適度買入”，平均目標價格為 9.21 美元。機構投資者持有 70.37% 的股份。Prime Medicine 專注於用於基因治療的基因編輯技術</p>

<p>Prime Medicine, Inc. (NYSE:PRME - Get Free Report)'s share price fell 7.2% during trading on Monday . The stock traded as low as $3.52 and last traded at $3.5450. 1,344,568 shares changed hands during trading, a decline of 54% from the average session volume of 2,896,184 shares. The stock had previously closed at $3.82.</p>
<div class="lb-trans"><p>Prime Medicine, Inc. (NYSE:PRME - 獲取免費報告) 的股價在週一交易中下跌了 7.2%。該股最低交易價為$3.52，最後交易價為$3.5450。在交易中，共成交了 1,344,568 股，較平均交易量 2,896,184 股下降了 54%。該股此前收盤價為$3.82。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Prime Medicine</strong> 相關提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>2 gene editing stocks to keep on your 2024 watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因編輯股票值得在 2024 年關注</li>
</ul>
</div><p>A number of brokerages have weighed in on PRME. Chardan Capital lowered their price target on Prime Medicine from $10.00 to $9.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, November 10th. Citigroup lowered their target price on shares of Prime Medicine from $5.00 to $4.25 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday, November 11th. Finally, Wedbush reiterated an &#34;outperform&#34; rating and set a $8.00 target price on shares of Prime Medicine in a research report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $9.21.</p>
<div class="lb-trans"><p>多家券商對 PRME 進行了評估。Chardan Capital 將 Prime Medicine 的目標價從$10.00 下調至$9.00，並在 11 月 10 日的研究報告中給予該股 “買入” 評級。花旗集團將 Prime Medicine 的目標價從$5.00 下調至$4.25，並在 11 月 11 日的報告中給予該股 “中性” 評級。最後，Wedbush 在 11 月 10 日的研究報告中重申了 “跑贏大盤” 評級，並將 Prime Medicine 的目標價設定為$8.00。一位研究分析師給予該股 “強烈買入” 評級，四位分析師給予 “買入” 評級，三位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為$9.21。</p>
</div><p><strong>Read Our Latest Research Report on PRME</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 PRME 的最新研究報告</strong></p>
</div><h2>Prime Medicine Price Performance</h2>
<div class="lb-trans"><h2>Prime Medicine 價格表現</h2>
</div><p>The stock has a 50 day moving average price of $4.86 and a two-hundred day moving average price of $3.70. The company has a market capitalization of $643.52 million, a price-to-earnings ratio of -1.74 and a beta of 2.64.</p>
<div class="lb-trans"><p>該股的 50 日移動平均價格為$4.86，200 日移動平均價格為$3.70。該公司的市值為 6.4352 億美元，市盈率為-1.74，貝塔值為 2.64。</p>
</div><h2>Hedge Funds Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>對 Prime Medicine 的對沖基金看法</h2>
</div><p>A number of large investors have recently modified their holdings of PRME. Creative Planning acquired a new position in Prime Medicine during the 2nd quarter worth $25,000. Freedom Investment Management Inc. bought a new stake in shares of Prime Medicine during the second quarter worth $26,000. R Squared Ltd acquired a new position in shares of Prime Medicine during the second quarter valued at $31,000. JTC Employer Solutions Trustee Ltd acquired a new position in shares of Prime Medicine during the second quarter valued at $33,000. Finally, Savant Capital LLC bought a new position in Prime Medicine in the second quarter valued at about $37,000. 70.37% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>多家大型投資者最近調整了對 PRME 的持股。Creative Planning 在第二季度新購入了 Prime Medicine 的股份，價值$25,000。Freedom Investment Management Inc.在第二季度購買了 Prime Medicine 的新股份，價值$26,000。R Squared Ltd 在第二季度新購入了 Prime Medicine 的股份，價值$31,000。JTC Employer Solutions Trustee Ltd 在第二季度新購入了 Prime Medicine 的股份，價值$33,000。最後，Savant Capital LLC 在第二季度新購入了 Prime Medicine 的股份，價值約$37,000。目前，70.37% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Prime Medicine Company Profile</h2>
<div class="lb-trans"><h2>Prime Medicine 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.是一家生物技術公司，通過部署基因編輯技術提供遺傳療法，以應對各種疾病。該公司提供 Prime Editors，包含一個 Prime Editor 蛋白質，由 Cas 蛋白和逆轉錄酶融合而成；以及一個 pegRNA，旨在將 Prime Editor 定位到特定基因組位置，並提供製作目標 DNA 序列所需編輯的模板。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>If D-Wave Is Too Risky, Consider These 3 Quantum ETFs for Diversification</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>NVIDIA’s 13F Reveals 2 Q3 Winners—And 1 Painful Miss</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>Why Silver Beat Gold and the S&amp;P in 2025—And What Comes Next</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Prime Medicine</li>
<li>投資者需要了解的擊敗市場的信息</li>
<li>如果 D-Wave 風險太大，請考慮這 3 只量子 ETF 進行多元化</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>NVIDIA 的 13F 揭示了 2 個第三季度贏家——以及 1 個痛苦的失誤</li>
<li>3 只最佳金融科技股票，助力投資組合提升</li>
<li>為什麼銀在 2025 年勝過黃金和標準普爾——接下來會發生什麼</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Prime Medicine 嗎？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Prime Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Prime Medicine 並不在名單上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prime Medicine 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Prime Medicine (NYSE:PRME) 的股價下跌了 7.2% - 以下是原因